Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | 12-2017 | 12-2006 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -184,594 | -211,505 | 0 | N/A |
| Depreciation Amortization | 1,431 | 464 | 0 | N/A |
| Accounts payable and accrued liabilities | -985 | 8,800 | N/A | N/A |
| Other Working Capital | -6,878 | 12,096 | 0 | N/A |
| Other Operating Activity | 53,676 | 145,492 | 0 | 0 |
| Operating Cash Flow | $-137,350 | $-44,653 | $0 | $N/A |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -50,791 | -5,332 | 0 | N/A |
| Purchase Of Investment | -257,703 | -649,307 | N/A | N/A |
| Sale Of Investment | 472,578 | 21,841 | N/A | N/A |
| Investing Cash Flow | $164,084 | $-632,798 | $0 | $N/A |
| Cash Flows From Financing Activities | ||||
| Change In Short Term Borrowing | N/A | 116,842 | N/A | N/A |
| Common Stock Issued | 58,960 | 355,059 | N/A | N/A |
| Other Financing Activity | 0 | 299,281 | 0 | 0 |
| Financing Cash Flow | $58,960 | $771,182 | $0 | $N/A |
| Beginning Cash Position | 93,731 | N/A | 0 | N/A |
| End Cash Position | 179,425 | 93,731 | 0 | N/A |
| Net Cash Flow | $85,694 | $93,731 | $0 | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | -137,350 | -44,653 | 0 | N/A |
| Capital Expenditure | -50,791 | -5,332 | N/A | N/A |
| Free Cash Flow | -188,141 | -49,985 | 0 | 0 |